Transdermal Naltrexone Patch with Penetration Enhancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery methods for naltrexone, such as oral tablets and depot injections, face challenges including patient non-compliance, adverse gastrointestinal effects, and inconsistent release rates, limiting its clinical effectiveness in treating alcoholism and opiate addiction.
Innovation Solution
Development of transdermal pharmaceutical compositions comprising naltrexone in combination with penetration enhancers like methyl oleate and isopropyl myristate, formulated into patches for controlled release, which allow for effective transdermal delivery of therapeutically relevant quantities of naltrexone.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oral administration of naltrexone is used, then the drug is well absorbed (96% absorption from gastrointestinal tract), but significant first pass metabolism occurs with oral bioavailability ranging from 5% to 40%, and adverse gastrointestinal effects occur
Solution Approach 1:
The patent introduces a transdermal patch as an intermediary delivery system that bypasses the gastrointestinal tract and first pass metabolism. The patch delivers naltrexone through the skin into the systemic circulation, eliminating the harmful gastrointestinal effects associated with oral administration while maintaining effective drug bioavailability.
2Ease of operation
If oral administration of naltrexone is used, then the drug can be administered conveniently, but patient non-compliance occurs and significant quantities of naltrexone remain in the body after the treatment period
Solution Approach 1:
The transdermal patch provides continuous, steady-state delivery of naltrexone over an extended period (up to 7 days), eliminating the need for daily oral dosing. This continuous action improves patient compliance by removing the daily reminder of medication taking while maintaining consistent therapeutic levels in the body.
3Ease of operation
If depot injections of naltrexone are used, then invasive administration is avoided, but inconsistent release rates and site-of injection reactions occur
Solution Approach 1:
The patent uses the skin as an intermediary delivery interface, replacing the invasive injection site with a non-invasive transdermal patch. This eliminates site-of-injection reactions while providing more consistent and reliable release rates through controlled transdermal diffusion, avoiding the variability associated with depot injections.
4Reliability
If high doses of naltrexone are administered to maintain therapeutic levels, then treatment efficacy is improved, but peak concentrations cause adverse effects and liver toxicity increases
Solution Approach 1:
The transdermal patch system provides periodic, controlled release of naltrexone over multiple days, maintaining therapeutic levels without creating harmful peak concentrations. This extended-release mechanism allows for lower total daily doses compared to oral administration, reducing liver toxicity while maintaining treatment efficacy through sustained plasma concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal delivery system enhances patient compliance, reduces gastrointestinal side effects, and provides a controlled release of naltrexone, maintaining therapeutic levels with reduced peak concentrations, thus improving treatment efficacy for alcoholism and opiate addiction.
Implementation Method 1
certain pharmaceutical compositions comprising naltrexone and specific penetration enhancers, sometimes known and referred to as permeation enhancers, permit the transdermal delivery of therapeutically relevant quantities of naltrexone. In particular we have found that compositions comprising naltrexone in combination with the compounds methyl oleate and/or isopropyl myristate are useful in this regard
Data Source
AI summary
The invention provides transdermal patches comprising an adhesive and a composition comprising naltrexone and methyl oleate or isopropyl myristate, a kit comprising a plurality of such transdermal patches, a composition comprising naltrexone and methyl oleate, such a composition for use as a medicament, and compositions comprising naltrexone and methyl oleate or isopropyl myristate for use in the treatment of alcoholism or opiate addiction.